Piper Jaffray believes NuVasive's Q2 results and the release of the final ruling on the Medtronic case should drive NuVasive shares to the $30 range. Piper thinks the stock could top $30 on better-than-expected Q2 results or a final Medtronic ruling leaving patent rates unchanged. The firm reiterates an Overweight rating on NuVasive with a $33 price target.
Investors can never escape all fear and threat of loss. But as a start, it helps to know what’s worth being afraid …